Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT

Khoo, Teh‐Liane; Catalano, Alberto; Supple, Shane G.; Li, Chong; Yeoh, Sue-Ching; Yeung, Stephen; Iland, Harry

doi:10.3109/10428194.2012.702904

Cited by 20 publications

(37 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Imatinib mesylate belongs to a new class of anticancer drugs that inhibits enzymes with tyrosine kinase activity; its targets are BCR‐ABL protein, c‐KIT, and PDGFR . Since 2001, when the drug was approved, it has revolutionized the management of patients with Philadelphia chromosome positive (Ph+) CML for which it represents the first‐line treatment . It is also indicated for the treatment of relapsed or refractory Ph+ acute lymphoblastic leukemia, some hematological diseases with PDGFR gene rearrangement (myelodysplastic/myeloproliferative diseases, hypereosinophilic syndrome, and/or chronic eosinophilic leukemia), metastatic and/or unresectable c‐Kit positive GIST, and unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans .…”

Section: Discussionmentioning

confidence: 99%

“…Imatinib mesylate (Glivec ® , formerly known as STI571, Novartis Pharma AG, Basel, Switzerland) is a tyrosine‐kinase inhibitor that targets BCR‐ABL protein, c‐Kit, and platelet derived growth factor receptor (PDGFR) . It is used for the treatment of several malignancies including chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST) .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Imatinib‐induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Imatinib‐induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The pathophysiological mechanism seems similar to that of hyperpigmentation due to antimalarials (drug metabolite deposition in the mucosa and complex formation with hemosiderin or melanin) [18]. Direct inhibition of c-kit (which is physiologically expressed in the oral mucosa) by imatinib has been also implicated in this mechanism by some authors [161,162].…”

Section: Pigmentary Changesmentioning

confidence: 95%

“…10) [161][162][163][164][165][166]. Pigmentation in other locations has been described in anecdotal reports [167].…”

Section: Pigmentary Changesmentioning

confidence: 99%

Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors

Vigarios

Epstein

Sibaud

2017

Support Care Cancer

148

136

View full text Add to dashboard Cite

Development of biological targeted therapies and immune checkpoint inhibitors has redefined the treatment for many cancers; however, the increasing use of new protocols has led to physicians observing a new spectrum of toxicities. To date, oral adverse events induced by these new anticancer therapies have been mainly reported using nonspecific terminology (Bstomatitis,^Bmucosal inflammation,^Bmucositis^) and remain poorly characterized, with the exception of mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis. Oral toxicities of targeted therapies often display very characteristic features which clearly differ from classic oral injuries observed with cytotoxic chemotherapy and/or radiotherapy. In addition, they frequently affect more than 20% of treated patients and can lead to a significant morbidity or permanent treatment discontinuation. Oral mucosal toxicities described in this review include mTOR inhibitor-associated stomatitis (mIAS); stomatitis, benign migratory glossitis, and osteonecrosis of the jaw associated with multi-targeted kinase inhibitors of the VEGF and PDGF receptors; mucositis induced by EGFR inhibitors (in monotherapy or in combination with head and neck radiotherapy and/or chemotherapy); hyperkeratotic lesions with BRAF inhibitors; pigmentary changes and lichenoid reactions secondary to imatinib; and more recent data on the BOsler-Weber-Rendu-like syndrome^described with the antibody-drug conjugate, TDM-1. Finally, we provide, to our knowledge, the first available structured data on oral toxicities induced by the new recently FDA-and EMA-approved monoclonal antibodies targeting PD-1. Clinical management of these targeted therapy-related oral changes is also discussed.

show abstract

Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review

et al. 2019

View full text Add to dashboard Cite

Objectives To assess the association between oral mucosa hyperpigmentation in patients with leukemia and imatinib mesylate use. Additionally, we compared our data to those obtained from a systematic review. Materials and methods A cross-sectional study was conducted with 74 patients undergoing treatment with imatinib mesylate. Sociodemographic characteristics, oral mucosa alterations, and medical history were evaluated. Oral hyperpigmentation was scored. The use of imatinib mesylate and hydroxyurea was evaluated. Association between oral hyperpigmentation and imatinib mesylate was assessed. A systematic review was also conducted to retrieve case reports or case series of patients with oral hyperpigmentation associated with imatinib mesylate. Results Among the 74 participants, 41 were male (55.4%) and 33 were female (44.6%). Participants' mean age was 49.3 years. Sixty-six (89.2%) patients developed hyperpigmented lesions in the hard palate mucosa. In multivariate analysis, patients who had used imatinib mesylate for > 72 months had a hyperpigmentation score 1.62 times higher than those who had used this medication during a shorter period. Patients who had used hydroxyurea for > 30 days had a hyperpigmentation score 1.43 times higher than those who had used this medication during a shorter period. The systematic review retrieved 20 clinical cases of patients undergoing imatinib mesylate treatment and exhibiting oral hyperpigmentation. Conclusions The development of oral hyperpigmentation is associated with imatinib mesylate use. Hydroxyurea seems to increment such an association. Clinical relevance To assist providers in the differential diagnosis of hyperpigmented lesions associated with imatinib mesylate, as well as in the clinical management of such lesions.

show abstract

Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT

Cited by 20 publications

References 13 publications

Imatinib‐induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature

Imatinib‐induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature

Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors

Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review

Contact Info

Product

Resources

About